Amylyx Pharmaceuticals (AMLX) Income towards Parent Company (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Income towards Parent Company of -$91.0 million for Q1 2026, down 153.29% year-over-year from $170.7 million in Q1 2025, and down 175.61% quarter-over-quarter from -$33.0 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Income towards Parent Company (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$91.0 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 153.29% year-over-year to -$91.0 million; the TTM figure through Mar 2026 stood at -$199.8 million (down 28.23% YoY), while the FY2025 annual figure was -$144.7 million, up 39.36% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$91.0 million, down from -$33.0 million in the prior quarter.
- The five-year high for Income towards Parent Company was $25.5 million in Q4 2024, with the low at -$118.8 million in Q1 2024.
- The 5-year median for Income towards Parent Company is -$41.4 million (2025), against an average of -$36.9 million.
- Peak annual rise in Income towards Parent Company reached 845.87% in 2024, while the deepest fall reached 7652.0% in 2024.
- Amylyx Pharmaceuticals' Income towards Parent Company stood at -$43.8 million in 2022, then jumped by 106.16% to $2.7 million in 2023, then jumped by 845.87% to $25.5 million in 2024, then sank by 229.36% to -$33.0 million in 2025, then sank by 175.61% to -$91.0 million in 2026.
- Business Quant data shows AMLX's Income towards Parent Company at -$91.0 million in Q1 2026, -$33.0 million in Q4 2025, and -$34.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -121.94 Mn |
| Mar 31, 2026 | -90.95 Mn |
| Dec 31, 2025 | -33.00 Mn |
| Sep 30, 2025 | -34.39 Mn |
| Jun 30, 2025 | -41.44 Mn |
| Mar 31, 2025 | -35.91 Mn |
| Dec 31, 2024 | 25.51 Mn |
| Sep 30, 2024 | -72.70 Mn |
| Jun 30, 2024 | -72.70 Mn |
| Mar 31, 2024 | -118.79 Mn |
| Dec 31, 2023 | 2.70 Mn |
| Sep 30, 2023 | 20.89 Mn |
| Jun 30, 2023 | 22.07 Mn |
| Mar 31, 2023 | 1.57 Mn |
| Dec 31, 2022 | -43.81 Mn |
| Sep 30, 2022 | -53.76 Mn |
| Jun 30, 2022 | -54.09 Mn |
| Mar 31, 2022 | -47.85 Mn |
| Dec 31, 2021 | -28.32 Mn |
| Sep 30, 2021 | -23.14 Mn |